Patent ID: 11918689
Assignee: TRIS PHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 14:
15. The extended release oral clonidine aqueous suspension according to claim 1, wherein the suspension provides one or more of the pharmacokinetic parameters for clonidine of:
(a) an arithmetic mean Cmax (pg/mL) of about 326 pg/mL to about 508 pg/mL; and/or
(b) an arithmetic mean AUC0-∞ (hr-pg/mL) of about 10,650 hr-pg/mL to about 16,650 hr-pg/mL; and/or
(c) an arithmetic mean Tmax (hr) of about 14 hours to 22 hours;
as assessed following dosing two times in a day separated by about 12 hours interval, 0.1 mg clonidine at each dosing time (i.e., at 0 and 12 hours) to provide a total daily dose of 0.2 mg clonidine, based on the equivalent to clonidine HCl.